



Multi Tier Basic Annual Drug List Updates

April 2024

TRADE NAME (generic name) or generic name	Brand/Generic Product	Description of Change
BREO ELLIPTA (fluticasone furoate-vilanterol aero powd ba 50-25 mcg/act)	Brand	Addition
CIBINQO (abrocitinib tab 100 mg)	Brand	Addition
CIBINQO (abrocitinib tab 200 mg)	Brand	Addition
CIBINQO (abrocitinib tab 50 mg)	Brand	Addition
GLYBURIDE MICRONIZED (glyburide micronized tab 1.5 mg)	Brand	Removal
GLYBURIDE MICRONIZED (glyburide micronized tab 3 mg)	Brand	Removal
GLYBURIDE MICRONIZED (glyburide micronized tab 6 mg)	Brand	Removal
KALYDECO (ivacaftor packet 5.8 mg)	Brand	Addition
MORPHINE SULFATE (morphine sulfate oral soln 10 mg/5ml)	Brand	Removal
OPVEE (nalmeferene hcl nasal spray 2.7 mg/0.1ml (base equiv))	Brand	Addition
PAXLOVID (nirmatrelvir tab 10 x 150 mg & ritonavir tab 10 x 100 mg pak)	Brand	Addition
PAXLOVID (nirmatrelvir tab 20 x 150 mg & ritonavir tab 10 x 100 mg pak)	Brand	Addition
TIBSOVO (ivosidenib tab 250 mg)	Brand	Addition
ZENPEP (pancrelipase (lip-prot-amyl) dr cap 60000-189600-252600 unit)	Brand	Addition

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Texas (BCBSTX) contracts with Prime Therapeutics to provide pharmacy benefit management and related other services. BCBSTX, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.